Literature DB >> 10586044

Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).

S D Pippig1, C Peña-Rossi, J Long, W R Godfrey, D J Fowell, S L Reiner, M L Birkeland, R M Locksley, A N Barclay, N Killeen.   

Abstract

CD134 (OX40) is a member of the TNF receptor family that is expressed on activated T lymphocytes. T cells from mice that lack expression of CD134 made strong responses to a range of challenges, but they showed impaired proliferation in response to direct stimulation through the TCR with monoclonal anti-CD3epsilon Ab. CD134-deficient mice controlled infection with Leishmania major, Nippostrongylus brasiliensis, and Theiler's murine encephalomyelitis virus, and they made overtly normal Ab responses to a variety of antigens. Thus, CD134 is not essential for many T cell responses in vivo, nor is it required for the provision of help to B cells. Nonetheless, a subtle role in the regulation of T cell reactivity is suggested by the effect of CD134 deficiency on in vitro T cell responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  A novel helper role for CD4 T cells.

Authors:  J M den Haan; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

3.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

4.  OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

Authors:  Naomi Kitamura; Satoshi Murata; Tomoyuki Ueki; Eiji Mekata; R Todd Reilly; Elizabeth M Jaffee; Tohru Tani
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

5.  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Authors:  Payal Mittal; Rebecca Abblett; Joseph M Ryan; Adam T Hagymasi; Archibald Agyekum-Yamoah; Julia Svedova; Steven L Reiner; Marie-Clare St Rose; Matthew P Hanley; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2018-01-05       Impact factor: 5.422

6.  Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation.

Authors:  Joao G Magalhaes; Stephen J Rubino; Leonardo H Travassos; Lionel Le Bourhis; Wei Duan; Gernot Sellge; Kaoru Geddes; Karou Geddes; Colin Reardon; Matthias Lechmann; Leticia A Carneiro; Thirumahal Selvanantham; Jorg H Fritz; Betsy C Taylor; David Artis; Tak Wah Mak; Michael R Comeau; Michael Croft; Stephen E Girardin; Dana J Philpott
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-19       Impact factor: 11.205

7.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

8.  CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction.

Authors:  Giorgia Gri; Silvia Piconese; Barbara Frossi; Vanessa Manfroi; Sonia Merluzzi; Claudio Tripodo; Antonella Viola; Sandra Odom; Juan Rivera; Mario P Colombo; Carlo E Pucillo
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

9.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

10.  OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

Authors:  Daniel Hirschhorn-Cymerman; Gabrielle A Rizzuto; Taha Merghoub; Adam D Cohen; Francesca Avogadri; Alexander M Lesokhin; Andrew D Weinberg; Jedd D Wolchok; Alan N Houghton
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.